| Autor: |
Acanda De La Rocha, Arlet M., Fader, Maggie, Coats, Ebony R., Espinal, Paula S., Berrios, Vanessa, Saghira, Cima, Sotto, Ileana, Shakya, Rojesh, Janvier, Michelin, Khatib, Ziad, Abdella, Haneen, Bittle, Mathew, Andrade-Feraud, Cristina M., Guilarte, Tomás R., McCafferty-Fernandez, Jennifer, Salyakina, Daria, Azzam, Diana J. |
| Předmět: |
|
| Zdroj: |
JCO Precision Oncology; 10/27/2021, Vol. 5, p1659-1665, 7p |
| Abstrakt: |
Although several reports have shown improved patient survival using DST-guided treatment in different cancers,[21] [24] current DST platforms have a limited ability to study the immune system and tumor microenvironment. Combining genomics and functional data further refines precision therapy, enhancing appropriate drug combination selection - even lacking actionable biomarkers - and ultimately improving clinical outcomes for pediatric patients with relapsed and/or recurrent tumors, establishing a new treatment paradigm in pediatric cancer. Nat Med; 23: 1028-1035, 2017 3 Brodin BA, Wennerberg K, Lidbrink E, et al: Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. Treatments for rhabdomyosarcoma (RMS) including sclerosing and spindle cell rhabdomyosarcoma (SRMS) remains challenging. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
